+86 16650237703
Author:Kangdi 27-10-2026
Pain Patch OEM Quality Agreement 2026: 11 Clauses to Negotiate Before You Sign
Signing a pain patch quality agreement and not sure which clauses actually matter? This guide walks through the 11 clauses that determine whether a quality agreement protects you or protects the factory: the acceptance criteria, the change control notification window, the audit rights, the batch record retention period, the deviation disclosure obligation, and the 4 clauses that buyers most often give away without realising. It is built for brand owners, procurement managers, and regulatory leads who are about to sign a document that will govern every batch they receive for the next three years.
By the end of this page you will know the 11 clauses and the specific language each one needs, the 4 clauses that buyers give away without noticing, the 7 numbers to negotiate, and the 3 clauses that are non-negotiable in a regulated market.
A quality agreement is the document that decides what happens when something goes wrong. The supply agreement decides the price and the volume. The quality agreement decides whether you can reject a batch, whether you find out about a formulation change before or after it ships, whether you can audit the line that made your product, and whether the factory's batch records exist in a form that would let you execute a targeted recall. Most buyers spend 20 hours negotiating the price and 20 minutes on the quality agreement, and then discover 18 months later that the 20 minutes is what they actually needed.
Bottom line. A pain patch quality agreement that protects the buyer has 11 clauses, and 4 of them are the ones buyers routinely give away: the acceptance criteria definition, the change control window, the deviation disclosure obligation, and the batch record retention period. Each of these four is worth more than a 3% price concession, and each is negotiable at the start of a relationship and almost impossible to add later. The good news is that a factory which produces well-written quality agreements for its serious customers will sign all 11 without much resistance, because the clauses describe what it already does.
Table of Contents
- What a quality agreement is, and what it is not
- The 11 clauses, in the order they should appear
- The 4 clauses buyers give away without noticing
- The 7 numbers to negotiate (and the realistic ranges)
- The 3 clauses that are non-negotiable in a regulated market
- Acceptance criteria: how to define a rejectable batch
- Change control: the notification window that decides everything
- Audit rights: what you can actually inspect, and when
- What to do when the factory refuses a clause
- FAQ: quality agreement questions buyers ask most
- About Kangdi Medical and our quality agreement
1. What a Quality Agreement Is, and What It Is Not
A quality agreement is a separate document from the supply agreement, and it exists because the two documents answer different questions.
| Document | Answers | Typical length | Who owns it internally |
|---|---|---|---|
| Supply agreement / purchase terms | Price, volume, lead time, payment, delivery, Incoterm, termination | 4-8 pages | Commercial / procurement |
| Quality agreement | Specifications, acceptance criteria, change control, audit rights, deviation reporting, records, recall cooperation, CAPA obligations | 6-15 pages | QA / regulatory |
| Technical specification annex | The exact product: formulation, dimensions, packaging, test methods, tolerances | 2-5 pages per SKU | Product development / QA |
Three things a quality agreement is not. It is not a substitute for the specification annex — the specification defines the product, and the quality agreement defines how the parties handle conformance and non-conformance to that specification. It is not a warranty — a warranty says the product will perform, and a quality agreement says how the parties will determine whether it did. And it is not enforceable in isolation — a quality agreement without a specification annex is a document about a product that has not been defined.
The reason this distinction matters commercially is that buyers who try to put everything into the supply agreement end up with a 4-page document that is too vague to enforce on quality and too detailed to negotiate quickly on price. The reason it matters operationally is that the personnel who know what the specification should say are not the personnel who negotiate the price, and the two conversations need to happen with different people in the room.
2. The 11 Clauses, in the Order They Should Appear
The 11 clauses below are the structure we recommend. They are in the order a quality agreement should present them, because each one builds on the one before it.
| # | Clause | What it must specify | Why it matters |
|---|---|---|---|
| 1 | Scope and product identification | Which SKUs, which specifications (by annex reference), which manufacturing sites, which effective date | Prevents the "this SKU was not covered" argument. Name the SKUs, not the category |
| 2 | Specifications and test methods | The annex reference, the test methods (with the standard number), the sampling plan, and the tolerance for each parameter | The specification is what makes acceptance criteria meaningful. Without test methods, the tolerance is unmeasurable |
| 3 | Acceptance criteria and release | What constitutes a conforming batch, who releases it, what the certificate of analysis must contain, and what documentation must accompany each shipment | This clause determines whether you can reject a batch at receiving. A vague acceptance clause means every rejection becomes a negotiation |
| 4 | Change control notification | The notification window before any change to formulation, process, equipment, supplier, or site, and the buyer's approval right | The single highest-value clause in the document. It determines whether you learn about a formulation change before or after 50,000 units ship |
| 5 | Deviation and out-of-specification disclosure | The obligation to disclose any batch that deviated from the specification during production, even if the batch was released | A factory that produces a deviated batch and releases it without telling you has given you a recalled product in advance |
| 6 | Audit rights | Notice period, scope of the audit, access to records and to the production floor, frequency, and who bears the cost | Without audit rights, the quality system is a set of claims. With them, it is a set of claims you can verify |
| 7 | Batch records and retention | What a batch record contains, the retention period, and the buyer's access to it on request | The batch record is what makes a targeted recall possible. A 2-year retention period is not enough for a 24-month shelf-life product |
| 8 | Non-conformance handling and CAPA | The rejection process, the investigation timeline, the corrective and preventive action obligation, and the closure criteria | Determines whether a rejected batch produces a real fix or a credit note and the same problem next quarter |
| 9 | Complaint handling and adverse event reporting | Who receives complaints, the reporting timeline to the other party, the format, and the threshold for a serious incident notification | Serious adverse event reporting clocks start on awareness, and the factory is often aware before the brand |
| 10 | Recall cooperation | Who decides the scope, who executes, who bears the cost by cause, and the maximum time to provide the distribution footprint | A recall that takes 5 days to establish the footprint becomes a market withdrawal |
| 11 | Term, review, and termination | The review cadence, what survives termination (records, recall obligations, confidentiality), and the transition obligations | Obligations that end when the supply ends leave you without recourse for the last two batches |
Clause 1 is the one that buyers most often write too broadly. "Quality agreement covering all transdermal patch products supplied by the manufacturer" sounds comprehensive and is actually unenforceable, because it does not identify which specification applies to which product. Name the SKU list explicitly, and attach the specification annex per SKU.
3. The 4 Clauses Buyers Give Away Without Noticing
The four clauses below are the ones that buyers most often accept in a diluted form because the factory's template words them plausibly. Each is worth more than a price concession, and each is much easier to negotiate at the start.
| # | Clause | How it gets diluted | What the diluted version costs you | The language to insist on |
|---|---|---|---|---|
| 1 | Acceptance criteria | "Batches shall conform to the agreed specifications" — with no sampling plan, no test method, and no definition of a conforming batch | Every rejection becomes a dispute about whether the batch conformed. You cannot prove non-conformance without a defined test | "A batch is conforming if the assay of 10 randomly sampled units is within 95.0-105.0% of label claim by the method in Annex B, and peel adhesion of 10 units is at or above the value in Annex B when tested per ASTM D3330" |
| 2 | Change control | "The manufacturer shall notify the buyer of material changes" — with no window, no definition of material, and no approval right | You are notified after the change. The definition of "material" is the factory's, not yours | "The manufacturer shall not implement any change to the formulation, the active ingredient supplier, the adhesive, the backing film, the manufacturing site, or the converting equipment without the buyer's prior written approval, requested at least 90 days before the intended implementation date" |
| 3 | Deviation disclosure | Omitted entirely, or covered by a general "the manufacturer shall maintain quality records" | A batch made with a process deviation is released to you as normal stock. You find out at the consumer complaint stage | "The manufacturer shall disclose to the buyer, within 5 business days of release, any batch where a process parameter deviated from the validated range, regardless of whether the batch met the release specification, and shall include the deviation report with the certificate of analysis" |
| 4 | Batch record retention | "Records shall be retained for 2 years" — often in the factory's boilerplate, rarely questioned | A 24-month shelf-life product with a 2-year record retention means the records expire at the same moment as the product, and a recall in month 20 has no traceability | "Batch records shall be retained for a minimum of 5 years from the date of manufacture, or 3 years after the expiry date of the last unit in the batch, whichever is longer, and shall be available to the buyer within 10 business days of a request" |
Clause 4 is the one that looks administrative and is not. A pain patch has a 24-month shelf life, which means a consumer could be using a unit 30 months after manufacture. If the batch record was retained for 2 years, it is gone, and a recall in month 26 cannot be executed at batch level. The 5-year minimum is the standard in most regulated manufacturing frameworks, and asking for it is a test of whether the factory has a real document control system or a filing cabinet.
4. The 7 Numbers to Negotiate (and the Realistic Ranges)
Quality agreements contain seven numbers that carry most of the operational risk. The table below gives the realistic range for each, and the position to argue for.
| # | Number | Typical factory position | Realistic range | Position to argue for |
|---|---|---|---|---|
| 1 | Change control notice window | 30 days | 30-90 days | 90 days for a formulation or site change; 30 days for a packaging or artwork change |
| 2 | Deviation disclosure window | Not specified | 3-10 business days | 5 business days from release, with the report attached to the CoA |
| 3 | Batch record retention | 2 years | 2-5 years | 5 years from manufacture, or 3 years after expiry, whichever is longer |
| 4 | Audit notice period | 30 days | 7-30 days | 15 days for a routine audit; 48 hours for a for-cause audit following a quality event |
| 5 | Rejection response time | 30 days | 10-30 days | 10 business days for an investigation plan, 30 days for the completed investigation |
| 6 | Serious adverse event notification | Not specified | 24-72 hours | 24 hours, because the regulatory clock in most markets is 15 days from awareness and the factory is often aware first |
| 7 | Recall footprint delivery | Not specified | 2-5 business days | 48 hours. This is the number that determines whether a batch recall stays a batch recall |
Numbers 6 and 7 are the two that most factories have never been asked for, and they are the two that matter most in an event. A factory that has never thought about a 24-hour serious adverse event notification will agree to it in principle and fail it in practice, which is why the mock recall in the article on recall readiness is the test of whether the clause is real.
5. The 3 Clauses That Are Non-Negotiable in a Regulated Market
Three clauses are not negotiable if the product is going into a market with a real regulator (EU, US, UK, Australia, Japan, Canada, and most of the GCC). A factory that refuses any of the three is not qualified for that market, regardless of its price.
- Change control with an approval right. Under EU MDR and FDA cGMP, a change to the formulation, the manufacturing site, or a critical supplier requires a regulatory assessment, and in most cases a notification or an approval before implementation. A quality agreement that allows the factory to change the formulation on notice, without the buyer's approval, puts the buyer in breach of its own regulatory obligations the moment the change happens. This is the clause that must be non-negotiable, and the argument for it is that the regulator requires it, not that the buyer prefers it.
- Deviation disclosure. A factory that will not commit to disclosing deviated batches is a factory that intends to decide for you whether a deviation is material. In a regulated market, the decision about whether a deviated batch is acceptable belongs to the party that holds the registration, and that is the buyer, not the factory.
- Batch record access and retention. Without a batch record, a targeted recall cannot be executed and a regulatory inspection cannot be answered. Both of those are the buyer's obligations, not the factory's, and a buyer cannot discharge an obligation it has no records for.
The argument that works with a factory on these three is not "our procurement policy requires it". It is: "our registration requires it, and if a regulator inspects and finds that we cannot produce the batch record or did not approve a formulation change, the registration is at risk — and if the registration is at risk, so is your order book." That framing converts the negotiation from a power contest into a shared risk conversation, and it is also true.
6. Acceptance Criteria: How to Define a Rejectable Batch
The acceptance criteria clause is where the quality agreement becomes operational. The table below sets out the parameters a pain patch acceptance clause should define, and what a complete definition looks like for each.
| Parameter | Test method to specify | Sampling | Typical tolerance | What a vague version looks like |
|---|---|---|---|---|
| Active ingredient assay | HPLC or GC, with the column and mobile phase referenced or attached | 10 units per batch, randomly drawn across the run | 95.0-105.0% of label claim | "The active content shall be as labelled" |
| Content uniformity | USP <905> or the equivalent | 10 units per batch | Acceptance value not more than 15.0 | Omitted entirely |
| Peel adhesion | ASTM D3330 or the equivalent 180-degree peel | 10 units per batch, on the specified substrate | A value at or above the annex threshold, and no unit below the minimum | "The patch shall adhere adequately" |
| Wear-time adhesion | Simulated wear over the full claimed period, on a skin analogue | 5 units per batch | Adhesion score at or above 4 for the full wear period | Omitted, or tested only at time zero |
| Dimensions | Caliper measurement | 10 units per batch | Length and width within ±1.0 mm; thickness within ±10% | "Standard size" |
| Microbial limits | Ph. Eur. or USP method, with the incubation conditions | 3 units per batch | TAMC <100 cfu/g, TYMC <10 cfu/g, specified pathogens absent | "The product shall be microbiologically clean" |
| Packaging integrity | Seal strength and dye penetration, or the specified leak test | 10 pouches per batch | No seal failure; seal strength at or above the annex threshold | "The packaging shall be intact" |
| Labelling accuracy | Visual check against the approved artwork, with a signed proof | Every batch | No deviation from the approved artwork file | Omitted entirely |
The labelling row is the one buyers forget, and it is the single most common cause of customs detention in this category. A batch with a perfect assay and a mistranslated warning is a non-conforming batch, and the quality agreement needs to say so explicitly, with the approved artwork file identified by version and date.
7. Change Control: The Notification Window That Decides Everything
Change control is the highest-value clause in the document, and it is worth understanding why before negotiating the window. The table below sets out the change types and the approval regime each should require.
| Change type | Examples | Required regime | Window |
|---|---|---|---|
| Formulation change | An active ratio, an excipient, an adhesive grade | Prior written approval required | 90 days minimum |
| Site change | A different manufacturing facility, a different line | Prior written approval required, plus a regulatory notification | 120 days minimum |
| Critical supplier change | A different active ingredient source, a different backing film supplier | Prior written approval required | 90 days minimum |
| Process change | A different mixing time, a different curing temperature, a different press pressure | Prior written notification, with the buyer's objection right | 60 days minimum |
| Equipment change | A new converting machine, a different die | Prior written notification, with sample validation | 60 days minimum |
| Packaging change | A different pouch material, a different carton | Prior written notification | 30 days minimum |
| Artwork change | A label revision | Buyer-driven only; the factory never initiates an artwork change | Per the artwork approval cycle |
Two practical notes. First, the window is measured from the notification, not from the implementation date, so a 90-day window means the factory notifies you 90 days before it intends to change something — not 90 days before you find out. Write it as "at least 90 days before the intended implementation date" to remove the ambiguity. Second, the artwork row is deliberately one-sided: the factory should never initiate an artwork change, because the artwork is yours. A clause that allows the factory to change packaging artwork on notice is a clause that allows it to alter your label compliance without your knowledge.
8. Audit Rights: What You Can Actually Inspect, and When
Audit rights are frequently granted in a form that sounds generous and delivers nothing. The table below sets out the four questions that determine whether an audit right is real.
| Question | Weak version | Strong version |
|---|---|---|
| What can be inspected? | "The buyer may audit the facility" | "The buyer may inspect the production area, the quality laboratory, the raw material store, the finished goods store, the batch records, the deviation log, the complaint log, the calibration records, and the training records" |
| Who can conduct it? | "The buyer may audit" — implying only the buyer's own staff | "The buyer or its nominated third party (including a notified body or a contract auditor) may conduct the audit" |
| With what notice? | 30 days, with no exception | 15 days for a routine audit; 48 hours for a for-cause audit following a quality event, a rejection, or a complaint trend |
| Who bears the cost? | Unspecified, which means the buyer assumes it or the audit does not happen | Buyer bears the cost for routine audits beyond the first per year; factory bears the cost for a for-cause audit that confirms a non-conformance |
The for-cause audit at 48 hours is the clause that matters, and it is the one factories resist most. A routine audit at 30 days' notice inspects a factory that has had 30 days to prepare. A for-cause audit at 48 hours inspects the factory as it actually is, which is the only version that matters after a quality event. The cost allocation in the fourth row makes it palatable: the factory bears the cost only if the audit confirms a non-conformance, which a factory confident in its system will accept.
9. What to Do When the Factory Refuses a Clause
A factory will refuse at least one clause. The table below is the decision framework for what a refusal tells you and what to do about it.
| Refused clause | What it tells you | What to do |
|---|---|---|
| Prior approval for formulation change | The factory intends to change formulations without telling you, which means your registration is exposed | Do not sign. This is the one refusal that is disqualifying in a regulated market |
| Deviation disclosure | The factory intends to decide alone whether a deviation is material | Do not sign. Offer to define a materiality threshold together if the concern is volume of disclosures, but keep the obligation |
| 5-year batch record retention | The factory's document control is a filing cabinet, or the records are not complete enough to keep | Negotiate down to 3 years after expiry if needed, but not to 2 years from manufacture |
| 48-hour for-cause audit | The factory is concerned about what an unprepared inspection would show | Negotiate to 5 business days, and keep the for-cause trigger. A 5-day audit right is still worth far more than a 30-day one |
| 48-hour recall footprint | The factory's traceability is batch-level in name only, and building the footprint takes weeks | This is a finding in itself. Require a mock footprint exercise before the first order, and treat the result as a qualification gate |
| 24-hour adverse event notification | The factory has no process for receiving or escalating complaints | Require a named contact and a documented escalation path as a condition of the first order |
The pattern across the table is that a refusal is information. A factory that refuses the 48-hour audit right has told you something about its quality system that you would otherwise have discovered during a recall. A factory that accepts all 11 clauses and then fails them in practice has told you nothing until the first batch fails. The negotiation is therefore as much a qualification exercise as a legal one, and the refusal pattern is worth recording in the supplier file.
10. FAQ: Quality Agreement Questions Buyers Ask Most
10.1 Is a quality agreement legally required?
In most regulated markets, a documented quality agreement between the legal manufacturer and a contract manufacturer is an expectation rather than an explicit statutory requirement, and it is treated as a requirement in practice during an inspection. In the EU, MDR Annex IX and the MDCG guidance on contract manufacturing expect the arrangement to be documented. In the US, the cGMP framework at 21 CFR 210/211 requires the contract manufacturer relationship to be defined in writing. A brand without one is exposed in an inspection and has no contractual basis for a rejection.
10.2 Can I use the factory's standard quality agreement template?
You can start from it, and you should read it carefully, because the standard template is written by the party that will be subject to the obligations. The four clauses in Section 3 are the ones most likely to be diluted in a factory template, and the seven numbers in Section 4 are the ones most likely to be set in the factory's favour. A practical approach is to accept the factory's structure and negotiate the substance: keep their clause order, replace their acceptance criteria, change control window, deviation disclosure, and retention period.
10.3 Does a quality agreement need to be signed by a lawyer?
It should be reviewed by one, and it should be negotiated by the QA lead. The two roles do different things: QA knows what the specification should say and what the acceptance criteria should be, and legal knows whether the obligations are enforceable and what survives termination. A quality agreement negotiated only by legal produces clauses that are enforceable and technically meaningless. One negotiated only by QA produces clauses that are technically correct and legally unenforceable.
10.4 How often should the quality agreement be reviewed?
Annually, and after any material change. An annual review is a 2-hour meeting with QA and the factory's quality manager, and it is the moment to update the specification annex, revise the tolerances, and confirm that the clauses still describe what both parties actually do. A quality agreement that has not been reviewed in 3 years usually describes a process that no longer exists.
10.5 What if the factory is also supplying my competitor?
That is normal and is not a quality agreement issue. What matters is that the specification annex defines your product precisely enough that the factory cannot substitute a competitor's configuration, and that the change control clause prevents the factory from changing your formulation to match a shared one. If a shared configuration is acceptable to you, say so explicitly in the annex rather than leaving it to the factory's discretion.
10.6 Can the quality agreement reference the factory's own SOPs instead of spelling everything out?
Yes, and this is often the most practical approach for the procedural elements: reference the factory's deviation procedure, its CAPA procedure, and its complaint procedure by document number and revision. The clause should require that the buyer receives the referenced documents, that changes to them are notified, and that the buyer's obligations under those procedures are stated. Referencing without those three conditions gives the factory the ability to change the procedure unilaterally.
10.7 Who owns the specification annex?
The buyer owns the specification, and the annex should say so, including the ownership of any formulation development work and the derived IP. This connects to the IP clauses in a brand protection agreement, and the two documents should not contradict each other. A specification annex that says the buyer owns the formulation and an IP agreement that says the factory owns the improvements is a contradiction that will be resolved against the party with the weaker position, which is usually the buyer.
10.8 What is the single most important clause?
Change control with a prior approval right. Every other clause in the document addresses what happens after something has gone wrong. Change control is the only clause that prevents the wrong thing from being manufactured in the first place, and it is the clause that protects the registration rather than merely the batch. If you can only negotiate one clause, negotiate that one.
10.9 Does Kangdi sign quality agreements with buyers?
Yes, and we sign them as a matter of standard practice rather than as a concession. Our standard quality agreement covers the 11 clauses in Section 2, with the acceptance criteria, change control window, deviation disclosure, and record retention already at the positions described in Section 3, because those are the positions our own quality system is built to. We also provide the specification annex per SKU and the test methods with the standard references. Email us with "Quality Agreement" and your SKU list, and we will send our standard template with two annotated sections: what you can change, and what we will not.
10.10 What happens if a batch is rejected under the agreement?
The rejection process should be defined in clause 8: written notice within a stated period of receipt, a joint investigation with a defined response timeline, and a defined remedy. The remedy should be specific — replacement, credit, or refund — and it should be chosen by the buyer rather than offered by the factory. A quality agreement that says the parties "shall resolve the issue amicably" has no rejection process, and in practice it means the buyer absorbs the loss.
11. About Kangdi Medical and Our Quality Agreement
Henan Kangdi Medical Devices Co., Ltd has manufactured transdermal patches since 1989 from a GMP-certified facility in Zhoukou, Henan, China, and we supply 200+ brand buyers and distributors across 40+ countries. Our quality agreement is a standard document rather than a negotiated exception, and it is written to the positions described in this guide.
Three steps to review our quality agreement. (1) Email us with "Quality Agreement" as the subject line and attach your SKU list. (2) We will send our standard template, the specification annex for each SKU, and the test methods, within 3 business days. (3) We will hold a 60-minute call with your QA lead to walk through the 11 clauses, mark what is negotiable and what is not, and agree the specification annex before the first order.
- Step 1: Email export@kangdimedical.com with "Quality Agreement" as the subject line, including your SKU list and the markets you sell into.
- Step 2: Receive our standard quality agreement template, the specification annex per SKU, and the test method references within 3 business days.
- Step 3: A 60-minute QA call to agree the annex and record the agreed positions on the 11 clauses before the first production order.
Tell us your SKU list and your target markets, and we will send the quality agreement package within 3 business days.